1/8

ANTIBODY COMBINATIONS

		302 -22	302-33	302-29	302-29
SAMPLE	SAMPLE #	302 - 18	107-7	302-18	107.7
NORMAL	1	0.0	0.0	0.0	0.0
NORMAL	2	0.0	0.0	0.0	0.0
NORMAL	3	0.0	0.0	0.0	0.0
NORMAL	4	0.0	0.0	0.0	0.0
NORMAL	5	0.0	0.0	0.0	0.0
NORMAL	6	0.0	0.0	0.0	0.0
NORMAL	7	0.0	0.0	0.0	0.0
NORMAL	8	0.0	0.0	0.0	0.0
NORMAL	9	0.0	0.0	0.5	0.0
NORMAL	10	0.0	0.7	1.2	0.0
NORMAL NORMAL	11 12	0.0	1.3	0.0	0.0
NORMAL	13	0.0 0.0	5.3 1.4	0.0 0.0	0.2
NORMAL	14 14	0.0	2.2	0.0	0.3 0.6
NORMAL	15	0.0	2.0	0.0	1.7
NORMAL	16	0.0	3.0	0.0	0.4
NORMAL	17	0.0	2.3	0.0	1.0
NORMAL	18	0.0	3.9	0.0	0.0
NORMAL	19	0.0	8.2	0.0	0.4
NORMAL	20	0.0	4.0	0.0	1.3
NORMAL	21	0.0	4.3	0.0	0.6
NORMAL	22	0.0	9.1	0.0	1.3
NORMAL	23	0.0	5.9	0.0	0.8
NORMAL	24	0.0	20.6	0.0	0.7
NORMAL	25	0.0	2.2	0.0	0.6
NORMAL	26	0.0	5.0	0.0	0.2
NORMAL	27 28	0.0	3.5	0.0	6.0
NORMAL NORMAL	28 29	0.9 1.4	10.1 3.3	0.9	0.7
NORMAL	30	1.4	3.3 1.5	0.0 1.4	1.0 1.2
NORMAL	31	1.9	6.9	3.9	1.0
NORMAL	32	2.1	0.0	0.0	6.3
NORMAL	33	2.8	8.9	0.0	0.0
NORMAL	34	4.1	28.4	6.6	0.8
NORMAL	35	4.2	28.6	5.4	0.0
NORMAL	36	11.0	11.6	5.6	0.0
BLADDER CA		0.0	0.0	0.0	0.0
BLADDER CA		36.7	1.6	0.0	0.0
BLADDER C	39	0.0	0.0	0.0	0.0
COLON CA	40	8.8	8.9	8.6	7.0
COLON CA	41	18.2	28.4	20.8	24.3
COLON CA	42	18.1	28.6	19.5	17.9
COLON CA	43	14.2	11.6	15.5	8.1
COLON CA	44	9.5	12.8	13.3	6.8
COLON CA	45	5.1	6.4	4.1	0.9
COLON CA	46	4.9	3.7	5.1	2.4

Fig. 1A

2/8

ANTIBODY COMBINATIONS

SAMPLE	SAMPLE	#	302 -22 302 - 18	302-33 107-7	302-29 302-18	302-29 107.7
PROSTATE	UM C 58 UM C 59 UM C 60 61 62 63 64 65 66 67 68 CA 69 CA 70		30.8 96.2 3.3 10.1 2.4 6.7 5.1 3.9 62.4 14.1 7.6 2.7 7.9 10.1 9.5 11.3 6.5 12.6 14.3 7.0 8.9 11.4 2.0	28.3 17.5 4.7 11.7 5.7 5.1 6.0 13.1 9.6 58.2 10.3 4.7 9.4 11.9 19.0 16.7 20.8 21.1 16.4 11.6 12.7 4.9	65.3 82.4 0.0 8.3 64.7 5.5 1.3 7.1 52.4 15.2 106.0 1.8 8.2 10.7 11.0 13.5 8.5 14.9 17.4 9.9 11.5 13.8 2.5	27.3 20.2 0.0 10.3 0.5 1.8 2.3 5.8 41.3 6.8 1.9 7.1 9.3 7.9 16.9 8.9 8.3 10.8 2.8
PROSTATE	CA 71 CA 72 CA 73		6.4 5.4 2.2	0.0 15.4 0.0	9.3 6.3 1.6	3.4 7.0 0.0

Inventor: Beausang et al.
Serial No.: Not yet assigned
Atty. Docket No.: MTP-012C4
Agent: Brian A. Fairchild

Express Mail Mailing Label No.: EL954731515US

TISSUE TYPE	ASSAY 1*	ASSAY 2**	ASSAY 3***
BREAST NORMAL 90-247	NT#	500	1250
BREAST NORMAL 90-252	7574	2705	5024
BREAST NORMAL 90-254	NT	1513	2789
BREAST NORMAL 90-264	NT	0	1685
BREAST NORMAL 90-268	139	NT	432
BREAST CANCER 90-256	438	NT	2750
BREAST CANCER 90-275	2000	NT	9429
BREAST CANCER 90-287	20222	7333	8600
CERVIX NORMAL 90-279	2500	NT	12571
CERVICAL CANCER 90-8083	12666	NT	70680
COLON NORMAL 90-253	1009	NT	1689
COLON CANCER 90-250	1450	NT	4275
KIDNEY NORMAL 90-259	4250	NT	4275
KIDNEY CANCER 90-289	2407	NT	5796
LIVER NORMAL	2154	614	202
LIVER NORMAL 90-451	NT	131	420
LIVER CANCER	2227	0	932
MET LIVER 90-403	NT	300	1133
LUNG NORMAL 90-248	4391	NT	6636
LUNG NORMAL 90-246	4200	NT	10000
LUNG NORMAL 90-107	NT	4166	388
LUNG NORMAL 90-118	NT	650	1200
LUNG CANCER 90-095	NT	5357	16077
LUNG CANCER 90-121	NT	>12000	40771
OVARIAN CANCER	8621	6517	2760
OVARIAN CANCER 90-260	6900	NT	20680
OVARIAN CANCER 90-291	2768	NT	5750
OVARIAN CANCER 90-291	NT	10909	14454
UTERINE CANCER 90-277	6574	NT	70684
UTERUS NORMAL 90-295	6574	NT	41444
AVERAGE NORMAL	3447	1284	5759
AVERAGE CANCER	9442	7069	26321

ASSAY 1 IS 107.7 SOLID PHASE AND 307.33 SOLUBLE PHASE.

^{**} ASSAY 2 IS 107.7 SOLID PHASE AND 302.29 SOLUBLE PHASE.

^{***} ASSAY 3 IS 302.18 SOLID PHASE AND 302.22 SOLUBLE PHASE.

[#] NT MEANS NOT TESTED.







Fig. 3



Inte: Nuclear Matrix Protein Fluid Assay Inventor: Beausang et al. Serial No.: Not yet assigned Atty. Docket No.: MTP-012C4 Agent: Brian A. Fairchild Express Mail Mailing Label No.: EL954731515US




Inte: Nuclear Matrix Protein Fluid Assay
Inventor: Beausang et al.
Serial No.: Not yet assigned
Atty. Docket No.: MTP-012C4
Agent: Brian A. Fairchild
Express Mail Mailing Label No.: EL954731515US



Inventor: Beausang et al. Serial No.: Not yet assigned Atty. Docket No.: MTP-012C4 Agent: Brian A. Fairchild

Express Mail Mailing Label No.: EL954731515US






Fig. 7